NCT07187505View on ClinicalTrials.gov

Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia

NAActive, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2027

Conditions
Acute Promyelocytic Leukemia (APL)
Interventions
DRUG

Venetoclax

Venetoclax is a selective BCL-2 inhibitor administered orally once daily. The dose will be adjusted according to the study protocol and patient tolerance.

DRUG

All-trans retinoic acid

All-Trans Retinoic Acid (ATRA) is administered orally, twice daily, as part of standard induction and consolidation therapy for acute promyelocytic leukemia.

DRUG

Arsenic Trioxide (ATO)

Arsenic Trioxide (ATO) is administered intravenously once daily, in combination with ATRA and venetoclax, during induction and consolidation therapy.

Trial Locations (1)

230022

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei

All Listed Sponsors
collaborator

The First Affiliated Hospital of Anhui Medical University

OTHER

lead

Anhui Medical University

OTHER

NCT07187505 - Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia | Biotech Hunter | Biotech Hunter